Asset profile

Chidamide

Small molecule

Ungradedevidence

Evidence outlook

Completed readouts not yet graded

This drug has completed mid- or late-stage studies whose evidence has not yet been graded on this platform. Where a sponsor has not posted registry results, topline data typically arrives via company announcements — see News.

How the evidence outlook works ↗

Upcoming events

(12 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (6)
September 2026 (1)
Phase 2Acute Monocytic Leukemia, Newly DiagnosedRecruiting
Est. primary completion 2026-09-30 · NCT05566054 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2026 (5)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2026-12-01 · NCT06220162 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2026-12-30 · NCT06451861 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Allogeneic Hematopoietic Cell Transplantation (HCT), AML (Acute Myeloid Leukemia)Recruiting
Est. primary completion 2026-12-31 · NCT07304232 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2HR+/HER2- Advanced Breast CancerNot yet recruiting
Est. primary completion 2026-12-31 · NCT06556862 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Leukemia, Myeloid, Acute, AML Stage, AdultRecruiting
Est. primary completion 2026-12-31 · NCT05603884 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2027 (3)
August 2027 (1)
Phase 2Acute Myeloid Leukemia, Adult, Newly DiagnosedRecruiting
Est. primary completion 2027-08-01 · NCT06532552 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2027 (1)
Phase 3Newly Diagnosed Acute Myeloid Leukemia (AML), Elderly PatientsRecruiting
Est. primary completion 2027-09-30 · NCT07514936 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2027 (1)
Phase 1/2Leukemia, Myeloid, AcuteRecruiting
Est. primary completion 2027-12-31 · NCT05270200 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2028 (2)
March 2028 (1)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-03-31 · NCT07412262 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2028 (1)
Phase 2AML (Acute Myeloid Leukemia)Not yet recruiting
Est. primary completion 2028-06-01 · NCT07643636 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2029 (1)
January 2029 (1)
Phase 2Relapsed/Refractory Acute Myeloid LeukemiaRecruiting
Est. primary completion 2029-01-31 · NCT06084819 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.